Sensitivity and specificity of PET parameters to discriminate between pSS patients with and without lymphoma
| . | Number of patients . | Sensitivity . | Specificity . | PPV . | NPV . |
|---|---|---|---|---|---|
| Separate items | |||||
| Par SUVmax > 3.1 | N = 69 | 76% (19/25) | 82% (36/44) | 70% (19/27) | 86% (36/42) |
| Subm SUVmax > 2.9 | N = 67 | 67% (16/24) | 84% (36/43) | 70% (16/23) | 82% (36/44) |
| Presence of nodular lung lesions | N = 70 | 31% (8/26) | 93% (41/44) | 73% (8/11) | 70% (41/59) |
| Combination scores | |||||
| 1 out of 3 present | N = 69 | 92% (24/26) | 67% (29/43) | 63% (24/38) | 94% (29/31) |
| 2 out of 3 present | N = 68 | 75% (18/24) | 91% (40/44) | 82% (18/22) | 87% (40/46) |
| . | Number of patients . | Sensitivity . | Specificity . | PPV . | NPV . |
|---|---|---|---|---|---|
| Separate items | |||||
| Par SUVmax > 3.1 | N = 69 | 76% (19/25) | 82% (36/44) | 70% (19/27) | 86% (36/42) |
| Subm SUVmax > 2.9 | N = 67 | 67% (16/24) | 84% (36/43) | 70% (16/23) | 82% (36/44) |
| Presence of nodular lung lesions | N = 70 | 31% (8/26) | 93% (41/44) | 73% (8/11) | 70% (41/59) |
| Combination scores | |||||
| 1 out of 3 present | N = 69 | 92% (24/26) | 67% (29/43) | 63% (24/38) | 94% (29/31) |
| 2 out of 3 present | N = 68 | 75% (18/24) | 91% (40/44) | 82% (18/22) | 87% (40/46) |
pSS: primary SS; PPV: positive predictive value; NPV: negative predictive value; Par: parotid gland; Subm: submandibular gland; SUVmax: maximum standardized uptake value.
Sensitivity and specificity of PET parameters to discriminate between pSS patients with and without lymphoma
| . | Number of patients . | Sensitivity . | Specificity . | PPV . | NPV . |
|---|---|---|---|---|---|
| Separate items | |||||
| Par SUVmax > 3.1 | N = 69 | 76% (19/25) | 82% (36/44) | 70% (19/27) | 86% (36/42) |
| Subm SUVmax > 2.9 | N = 67 | 67% (16/24) | 84% (36/43) | 70% (16/23) | 82% (36/44) |
| Presence of nodular lung lesions | N = 70 | 31% (8/26) | 93% (41/44) | 73% (8/11) | 70% (41/59) |
| Combination scores | |||||
| 1 out of 3 present | N = 69 | 92% (24/26) | 67% (29/43) | 63% (24/38) | 94% (29/31) |
| 2 out of 3 present | N = 68 | 75% (18/24) | 91% (40/44) | 82% (18/22) | 87% (40/46) |
| . | Number of patients . | Sensitivity . | Specificity . | PPV . | NPV . |
|---|---|---|---|---|---|
| Separate items | |||||
| Par SUVmax > 3.1 | N = 69 | 76% (19/25) | 82% (36/44) | 70% (19/27) | 86% (36/42) |
| Subm SUVmax > 2.9 | N = 67 | 67% (16/24) | 84% (36/43) | 70% (16/23) | 82% (36/44) |
| Presence of nodular lung lesions | N = 70 | 31% (8/26) | 93% (41/44) | 73% (8/11) | 70% (41/59) |
| Combination scores | |||||
| 1 out of 3 present | N = 69 | 92% (24/26) | 67% (29/43) | 63% (24/38) | 94% (29/31) |
| 2 out of 3 present | N = 68 | 75% (18/24) | 91% (40/44) | 82% (18/22) | 87% (40/46) |
pSS: primary SS; PPV: positive predictive value; NPV: negative predictive value; Par: parotid gland; Subm: submandibular gland; SUVmax: maximum standardized uptake value.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
